Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.43 |
| ▸ | CCND1 | P24385 | 4/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | PRKCB | P05771 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | PRKACG | P22612 | 1/20 | 0.40 |
| ▸ | PRKACB | P22694 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522768 | 1.00 | CDK4 (0.43) | CDK4CCND1NOTUMKMT2ATSHR | |
| SCHEMBL9054617 | 0.72 | CDK4 (0.57) | CDK4CCND1KMT2AHTTHTR6 | |
| SCHEMBL28281993 | 0.71 | ALDH1A1 (0.43) | KMT2AMEN1HTR6RAB9AALDH1A1 | |
| SCHEMBL4658069 | 0.71 | NOTUM (0.53) | CDK4CCND1NOTUMKMT2ATSHR | |
| SCHEMBL10977944 | 0.70 | SLC6A2 (0.40) | CDK4CCND1NOTUM | |
| SCHEMBL4078165 | 0.70 | CDK4 (0.63) | CDK4CCND1KMT2AHTTLMNA | |
| SCHEMBL186381 | 0.69 | ALDH1A1 (0.49) | KMT2AL3MBTL1MEN1HTTALDH1A1 | |
| SCHEMBL1051084 | 0.69 | CA12 (0.50) | CDK4CCND1NOTUMKMT2ATSHR | |
| SCHEMBL5661381 | 0.69 | ALDH1A1 (0.44) | KMT2AHTTLMNAPRKD3PRKCG | |
| SCHEMBL5659240 | 0.69 | BIRC5 (0.57) | KMT2AMEN1LMNARAB9APRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319670-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| US-20240066023-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIVERSITARIO ANA G. MENDEZ, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11786520-B2 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIV ANA G MENDEZ INC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11311531-B2 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIV ANA G MENDEZ INC (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-20210290615-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIVERSITARIO ANA G. MENDEZ, INC. (US) | 2021-09-23 | — | — | US | disclosed |
| US-20200261441-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIVERSITARIO ANA G. MENDEZ, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200246328-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | SISTEMA UNIVERSITARIO ANA G. MENDEZ, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | C&C RESEARCH LABORATORIES (KR) | 2020-02-18 | — | — | US | disclosed |
| CN-104870422-B | Amine derivative or its salt | 富士胶片富山化学株式会社 | 2019-03-15 | — | — | CN | disclosed |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-13 | — | — | US | disclosed |
| US-20040092564-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-13 | — | — | US | disclosed |
| US-20040087637-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-06 | — | — | US | disclosed |
| US-6710069-B2 | FOR THERAPY OF CENTRAL NERVOUS SYSTEM DISORDERS | WYETH | 2004-03-23 | — | — | US | disclosed |
| EP-1353904-A1 | 1-ARYL-OR 1-ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030149018-A1 | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-08-07 | — | — | US | disclosed |
| US-6509357-B1 | Use there of for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. Various central nervous system disorders such as anxiety, depression, motor disorders, etc., are believed to involve a disturbance of the | WYETH | 2003-01-21 | — | — | US | disclosed |
| WO-2002059088-A1 | 1-ARYL-OR 1-ALKYLSULFONYLBENZAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-08-01 | — | — | WO | disclosed |
| US-3934017-A | Anthelmintic composition and method utilizing isothiocyanobenzazoles active ingredients | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
| US-3933841-A | ANTHELMINTICS | CIBA-GEIGY CORPORATION (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786520-B2 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | AHNAK, RECQL, NBAS | CDK4 1620/4885CCND1 1484/4885NOTUM 4116/4885 |
| US-11311531-B2 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | RECQL, AHNAK, NDUFS1 | CDK4 1735/4885CCND1 1837/4885NOTUM 4100/4885 |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | CDK4 483/4885CCND1 1051/4885NOTUM 3259/4885 |
| US-20200246328-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | RECQL, AHNAK, NDUFS1 | CDK4 1735/4885CCND1 1837/4885NOTUM 4100/4885 |
| US-20030149018-A1 | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | CDK4 2311/4885CCND1 3557/4885NOTUM 3441/4885 |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | CDK4 483/4885CCND1 1051/4885NOTUM 3259/4885 |
| US-20210290615-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | AHNAK, RECQL, NBAS | CDK4 1620/4885CCND1 1484/4885NOTUM 4116/4885 |
| US-20040087637-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | CDK4 2311/4885CCND1 3557/4885NOTUM 3441/4885 |
| US-10562912-B2 | Heterocyclic derivatives and use thereof | STAT3, JAK2, STAT5A | CDK4 890/4885CCND1 2774/4885NOTUM 3726/4885 |
| US-20040092564-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | CDK4 2311/4885CCND1 3557/4885NOTUM 3441/4885 |
| US-20050009819-A1 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | CDK4 2262/4885CCND1 3611/4885NOTUM 3227/4885 |
| US-20240066023-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | AHNAK, RECQL, NBAS | CDK4 1620/4885CCND1 1484/4885NOTUM 4116/4885 |
| US-20200261441-A1 | Method for producing benzazoloquinolium (BQs) salts and using the biological activity of the composition | RECQL, AHNAK, NDUFS1 | CDK4 1735/4885CCND1 1837/4885NOTUM 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.